What Is Aspergillosis? Symptoms, Causes, Diagnosis, Treatment, and Prevention

What Is Aspergillosis?

Aspergillosis is an illness caused by fungi in the genus Aspergillus. These molds are common throughout the environment. They grow in soil, compost, decaying leaves, stored plant material, household dust, and some damp indoor spaces. Their microscopic spores can float through the air and enter the body when a person breathes.

Exposure is extremely common, but disease is not. Healthy lungs have several layers of defense, including mucus, airway-clearing structures and immune cells such as macrophages and neutrophils. Together, they usually dispose of spores before the fungus can unpack its luggage and move in.

Problems are more likely when the airways are unusually sensitive, the lungs contain damaged areas or cavities, or the immune system cannot mount an effective response. Aspergillosis usually affects the lungs and sinuses, although invasive disease can spread to the brain, kidneys, heart, skin, bones or other organs.

Is aspergillosis contagious?

No. Pulmonary aspergillosis does not normally spread from one person to another or between people and animals. Patients typically acquire it by inhaling spores from the environment rather than by catching it from someone who is ill.

Main Types of Aspergillosis

The term “aspergillosis” covers several distinct conditions. The major forms include allergic bronchopulmonary aspergillosis, aspergilloma, chronic pulmonary aspergillosis and invasive aspergillosis.

Allergic bronchopulmonary aspergillosis

Allergic bronchopulmonary aspergillosis, or ABPA, is an exaggerated immune reaction to Aspergillus in the airways. The fungus does not necessarily invade lung tissue. Instead, the immune system responds too enthusiastically, producing inflammation, thick mucus and worsening airway obstruction.

ABPA occurs most often in people with asthma or cystic fibrosis. It may resemble repeated asthma attacks or pneumonia. Without appropriate management, recurrent inflammation can contribute to bronchiectasis, a condition in which airways become permanently widened and less efficient at clearing mucus.

Aspergilloma

An aspergilloma, informally called a fungus ball, is a tangled mass of fungal fibers, mucus and cellular debris. It typically develops inside a preexisting cavity in the lung. Such cavities may remain after tuberculosis, sarcoidosis, bronchiectasis, a lung abscess or another structural lung disorder.

Some aspergillomas cause no symptoms and are discovered during imaging performed for another reason. Others irritate nearby tissue and blood vessels, potentially causing repeated or severe coughing up of blood.

Chronic pulmonary aspergillosis

Chronic pulmonary aspergillosis develops gradually, generally over at least several months. It is most common in people with structural lung disease, including chronic obstructive pulmonary disease, previous tuberculosis, emphysema, sarcoidosis or bronchiectasis.

The infection may enlarge existing cavities, create new ones, cause lung scarring and reduce respiratory function. Some patients also develop one or more aspergillomas within the affected areas.

Invasive aspergillosis

Invasive aspergillosis is the most dangerous form. The fungus grows into lung tissue and may invade blood vessels. From there, it can spread to distant organs. This condition primarily affects people with severely weakened immune defenses, although it is also recognized in some critically ill patients with severe respiratory infections.

Because invasive aspergillosis can progress quickly, suspected cases require urgent specialist evaluation. Waiting for every test result before beginning treatment may not be appropriate when clinical suspicion is high.

Other forms

Aspergillus can also cause allergic or invasive sinus disease and, less commonly, infections of the ear canal, skin, nails, eyes, bones or heart. The location often depends on how the organism entered the body and the person’s underlying health.

Aspergillosis Symptoms

Symptoms depend on the type of aspergillosis and the part of the body affected. Cough and shortness of breath occur in several forms, but those symptoms are hardly exclusive to fungal disease. That overlap is one reason aspergillosis can masquerade as asthma, bacterial pneumonia, tuberculosis, lung cancer or another respiratory problem.

Symptoms of allergic bronchopulmonary aspergillosis

• Worsening asthma or more frequent asthma attacks
• Wheezing and chest tightness
• Persistent cough
• Brown, greenish or blood-streaked mucus plugs
• Low-grade fever
• Shortness of breath
• Fatigue or a general feeling of illness

Symptoms of an aspergilloma

• No symptoms in some cases
• Chronic cough
• Coughing up blood, known as hemoptysis
• Chest discomfort
• Fatigue
• Shortness of breath
• Unintentional weight loss

Symptoms of chronic pulmonary aspergillosis

• A cough lasting for months
• Increasing breathlessness
• Fatigue and reduced exercise tolerance
• Loss of appetite
• Unintentional weight loss
• Occasional fever or night sweats
• Coughing up blood

Symptoms of invasive aspergillosis

• Fever that does not improve with antibiotics
• Cough, sometimes with blood
• Sharp chest pain that may worsen with breathing
• Shortness of breath or falling oxygen levels
• Chills and profound fatigue
• Severe headache, confusion, weakness or seizures if the brain is involved
• Facial swelling, nasal pain or vision changes if the sinuses are involved
• Skin lesions if infection reaches or begins in the skin

Seek urgent medical care for significant coughing up of blood, severe breathing difficulty, confusion, new neurological symptoms or rapidly worsening illness. A fever in a person receiving chemotherapy, transplant medication or another powerful immunosuppressant also deserves prompt medical attention.

What Causes Aspergillosis?

Aspergillosis begins when susceptible individuals inhale airborne Aspergillus spores. Less commonly, the fungus may enter through damaged skin or a contaminated wound. Simply finding mold in a building does not prove that it caused a person’s symptoms, and everyday exposure does not usually lead to infection.

Several species can cause human disease. Aspergillus fumigatus is the most frequent cause of invasive pulmonary infection, while A. flavus, A. terreus and A. niger are also clinically important.

Who is most at risk?

Risk varies by disease type. People with asthma or cystic fibrosis are more susceptible to ABPA. Those with cavities or structural damage in the lungs are more likely to develop chronic pulmonary aspergillosis or an aspergilloma.

Risk factors for invasive aspergillosis include:

• Prolonged neutropenia, meaning very low levels of infection-fighting neutrophils
• Leukemia, lymphoma and certain other blood cancers
• Stem cell or solid-organ transplantation
• Graft-versus-host disease
• High-dose or prolonged corticosteroid treatment
• Chemotherapy and other immune-suppressing medications
• Inherited disorders that impair immune-cell function
• Advanced HIV infection
• Severe influenza, COVID-19 or another critical respiratory illness
• Extended intensive-care treatment in selected high-risk patients

Not every person with one of these factors will develop aspergillosis. Risk depends on the intensity and duration of immune suppression, existing lung damage, environmental exposure and other medical circumstances.

How Aspergillosis Is Diagnosed

There is no universal “yes or no” test that diagnoses every form of aspergillosis. Doctors combine the patient’s symptoms, immune status, lung history, imaging and laboratory results. A positive sputum culture alone may represent harmless colonization rather than active disease, especially in someone with chronic lung problems.

Medical history and physical examination

A clinician will review asthma control, previous lung infections, transplant history, cancer treatment, medication use and environmental exposures. The examination may include listening for wheezing or abnormal breath sounds and checking oxygen levels.

Imaging tests

Chest X-rays may reveal cavities, masses or areas resembling pneumonia. Computed tomography is more sensitive and can identify nodules, cavity walls, fungus balls and patterns suggesting invasive pulmonary disease. A CT scan is generally preferred when invasive aspergillosis is suspected, even when a standard chest X-ray appears unrevealing.

Blood and allergy testing

Tests for total IgE, Aspergillus-specific IgE, specific antibodies and eosinophil levels can help evaluate ABPA. Aspergillus IgG antibody testing is particularly useful in chronic pulmonary aspergillosis.

In certain high-risk patients, clinicians may use fungal biomarkers such as galactomannan or beta-D-glucan. These tests can support a diagnosis but are not perfect. Beta-D-glucan is not specific to Aspergillus, while the accuracy of galactomannan varies according to the specimen and patient population.

Sputum culture and molecular testing

A laboratory can examine mucus for fungal structures and attempt to grow the organism. Susceptibility testing may help determine whether the fungus is resistant to commonly used antifungal drugs. Polymerase chain reaction testing may detect fungal genetic material and is often interpreted alongside cultures, biomarkers and imaging.

Bronchoscopy and biopsy

During bronchoscopy, a specialist passes a thin flexible instrument into the airways and collects fluid through bronchoalveolar lavage. Testing that fluid may improve diagnostic accuracy. A tissue biopsy can provide the clearest evidence of invasive disease by showing fungus growing into tissue, although biopsy is not safe or necessary for every patient.

Aspergillosis Treatment

Treatment depends on the exact form of disease. Antifungal therapy that is appropriate for invasive infection may not solve a freely moving fungus ball, while ABPA treatment often focuses heavily on controlling inflammation. In other words, this is not a “grab any antifungal cream from the pharmacy” situation.

Treating allergic bronchopulmonary aspergillosis

Oral corticosteroids may be used to reduce allergic inflammation, particularly during active ABPA flares. Antifungal medicines such as itraconazole or another mold-active azole may reduce the fungal burden in the airways and decrease repeated inflammation. Selected patients with severe or difficult-to-control disease may also receive asthma biologic therapy under specialist supervision.

Doctors may monitor symptoms, lung function, imaging, eosinophil counts and IgE levels because lung damage can progress even when day-to-day symptoms seem tolerable.

Treating chronic pulmonary aspergillosis

Chronic pulmonary disease often requires months of oral antifungal therapy. Itraconazole, voriconazole or another appropriate azole may be selected based on fungal susceptibility, side effects, medication interactions and the patient’s overall condition.

Follow-up commonly includes imaging, blood tests, symptom assessment and sometimes measurements of antifungal drug levels. Treatment can be lengthy because chronic aspergillosis is rarely impressed by a seven-day prescription and a motivational speech.

Treating an aspergilloma

An asymptomatic, stable aspergilloma may be monitored rather than treated immediately. Antifungal medicine may have limited ability to penetrate a dense fungus ball. Surgery may be considered when the mass can be safely removed, particularly if it causes significant or repeated bleeding.

For severe hemoptysis, clinicians may use bronchial artery embolization to block the bleeding vessel. This can control an emergency, although bleeding may recur if the underlying fungal disease remains.

Treating invasive aspergillosis

Invasive aspergillosis requires urgent systemic antifungal treatment. A mold-active triazole such as voriconazole is commonly used as initial therapy, while isavuconazole is another primary option in appropriate patients. Liposomal amphotericin B may be selected when azole resistance, intolerance, drug interactions or other clinical factors make it preferable.

Therapy generally continues for weeks or months, depending on the infection site, immune recovery and response to treatment. Surgery may be required for selected infections involving the sinuses, heart, brain, bones or areas threatening major blood vessels.

Whenever medically possible, clinicians also address the underlying immune problemfor example, helping neutrophil counts recover or reducing immunosuppressive medication. These decisions must be carefully coordinated because abruptly changing transplant, cancer or inflammatory-disease treatment can create serious risks of its own.

Monitoring side effects and resistance

Azole antifungals can interact with many prescription drugs and may affect the liver, heart rhythm, nervous system or vision. Blood-level monitoring is recommended in several treatment situations to confirm adequate exposure and reduce toxicity. Patients should give their care team a complete list of prescriptions, over-the-counter products and supplements.

Azole-resistant A. fumigatus is an emerging concern. When treatment fails or resistance is suspected, fungal culture and susceptibility testing can help specialists choose an alternative medicine or combination strategy.

Can Aspergillosis Be Prevented?

Because Aspergillus spores are widespread, completely avoiding them is unrealistic. Most healthy people do not need to change their daily routines. Prevention measures are mainly intended for people at high risk of invasive infection or those whose specialists have provided individual precautions.

Ways high-risk individuals can reduce exposure

• Avoid construction, demolition and excavation areas when possible.
• Wear a properly fitted N95 respirator if a dusty area cannot be avoided.
• Limit close contact with soil, compost, mulch, grain dust and piles of decaying leaves.
• Use gloves, long sleeves, pants and closed shoes during necessary outdoor work.
• Clean cuts and scrapes promptly with soap and water.
• Do not personally clean major mold contamination without professional guidance.
• Follow hospital protective-environment instructions during periods of severe immune suppression.

Some transplant recipients, patients with prolonged neutropenia and other carefully defined high-risk groups may receive preventive antifungal medication. Prophylaxis is not appropriate for everyone because these drugs can cause toxicity, interact with other medications and promote resistance.

Managing asthma, cystic fibrosis, COPD and other lung disorders may also help clinicians recognize changes earlier. Patients at risk should know which symptoms require a call to their care team rather than assuming every cough is “just the weather.”

What Is the Outlook?

The prognosis depends heavily on the type of aspergillosis. ABPA can often be controlled, but relapses are possible and untreated inflammation may contribute to permanent airway damage. Chronic pulmonary aspergillosis may stabilize with long-term treatment, although some patients experience progressive loss of lung function.

A small, asymptomatic aspergilloma may remain stable for years. The outlook becomes more concerning when significant bleeding develops or surgery is not feasible.

Invasive aspergillosis is life-threatening, particularly when diagnosis is delayed, the infection spreads beyond the lungs or severe immune suppression continues. Early recognition, prompt antifungal therapy, resistance testing and recovery of immune function can meaningfully improve the chance of a successful outcome.

Living Through Testing and Treatment: Patient Experience Examples

The following examples are fictional composites created to illustrate common experiences. They do not describe identifiable patients and should not be used for self-diagnosis.

When “bad asthma” turns out to be ABPA

Imagine a person named Rachel who has managed asthma since childhood. During one unusually rough year, she needs several steroid bursts, wakes up wheezing and begins coughing up thick brown mucus. Antibiotics help brieflyor perhaps the symptoms merely happen to improve while she is taking thembut the problem keeps returning.

At first, Rachel assumes her asthma has simply become moodier with age. Her pulmonologist notices that some chest X-ray abnormalities appear in one location and later show up elsewhere. Blood testing reveals elevated IgE and eosinophils, and additional testing shows sensitivity to Aspergillus. A CT scan finds bronchiectasis and mucus-filled airways, supporting a diagnosis of ABPA.

The diagnosis brings mixed emotions. There is relief because the repeated attacks finally have an explanation, but the treatment plan is more involved than picking up another rescue inhaler. Rachel takes medication to reduce inflammation, receives an antifungal drug and schedules blood tests to monitor treatment. She learns that improvement may be gradual and that laboratory markers can change before she feels dramatically different.

She also becomes more systematic. Instead of vaguely telling her doctor that breathing has been “kind of bad,” she tracks nighttime symptoms, peak-flow readings, steroid use and mucus changes. That record helps the care team distinguish an ordinary asthma fluctuation from a possible ABPA relapse.

A transplant patient with a persistent fever

Now consider David, a fictional stem cell transplant recipient. During a period of severe neutropenia, he develops a fever. Broad-spectrum antibiotics are started because bacterial infections are common and dangerous in this setting. After several days, however, the fever continues and he develops a dry cough and mild chest discomfort.

Because David is at high risk for invasive fungal disease, his team does not wait for dramatic respiratory symptoms. A chest CT reveals suspicious nodules even though an earlier X-ray was not especially revealing. Blood biomarkers and bronchoscopy samples are obtained, and antifungal treatment begins while the team completes the diagnostic workup.

David’s experience illustrates why invasive aspergillosis can be stressful for patients and families. There may be no single definitive result on day one. Doctors make decisions by combining risk, imaging, laboratory findings and the patient’s clinical direction. Medications may change because of liver tests, drug interactions, blood levels or laboratory evidence of resistance.

Recovery is rarely measured by one magical morning when everything feels normal. Fever control, oxygen needs, immune recovery, CT findings and fungal markers may improve at different speeds. Imaging abnormalities can even look larger early in treatment as the immune system recovers, so the care team interprets each scan in context rather than declaring defeat based on one picture.

The emotional side of aspergillosis

Across allergic, chronic and invasive disease, uncertainty is often one of the hardest parts. Patients may wonder whether a cough represents a relapse, a common virus or simple airway irritation. Long medication courses can also affect work schedules, appetite, energy, finances and family routines.

Useful coping strategies include keeping an updated medication list, writing questions before appointments, bringing a trusted person to complex visits and asking exactly which symptoms should trigger an urgent call. Patients taking azole antifungals should report new side effects and medication changes rather than trying to “tough it out.” Pharmacists, pulmonologists, allergists, infectious-disease physicians and transplant or oncology teams may all play a role.

The central lesson is not to become suspicious of every leaf pile in the neighborhood. It is to understand personal risk, recognize meaningful changes and work with clinicians who can identify the specific form of aspergillosis. The fungus may be common, but the care plan should be highly individualized.

Conclusion

Aspergillosis is a broad family of illnesses caused by a common environmental mold. For one person, it may appear as worsening asthma; for another, it may form a fungus ball inside an old lung cavity. In someone with severe immune suppression, it can become an emergency that spreads beyond the lungs.

Accurate diagnosis requires more than matching symptoms to an online checklist. Medical history, CT imaging, cultures, antibody tests, fungal biomarkers, bronchoscopy and tissue examination may all contribute. Treatment can involve corticosteroids, long-term antifungal medication, surgery, embolization or measures that help immune defenses recover.

Most people do not need to fear everyday exposure to Aspergillus. Those with significant immune suppression or chronic lung disease should discuss their individual risk, prevention measures and warning signs with a healthcare professional.